Erratum: Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma (Neuro-Oncology (2015) 17:6 (862-867) DOI:10.1093/neuonc/nou350);Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma

Neuro-Oncology

Volumn 17, Issue 6, 2015, Pages 862-867

  Lee, Eudocia Q ^a   Reardon, David A ^a   Schiff, David ^b   Drappatz, Jan ^c   Muzikansky, Alona ^a   Grimm, Sean A ^d   Norden, Andrew D ^a   Nayak, Lakshmi ^a   Beroukhim, Rameen ^a   Rinne, Mikael L ^a   Chi, Andrew S ^a   Batchelor, Tracy T ^a   Hempfling, Kelly ^a   McCluskey, Christine ^a   Smith, Katrina H ^a   Gaffey, Sarah C ^a   Wrigley, Brendan ^a   Ligon, Keith L ^a   Raizer, Jeffrey J ^e   Wen, Patrick Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d CENTRAL DUPAGE HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anaplastic glioma; Antiangiogenesis,; Bevacizumab; Glioblastoma; Panobinostat

Indexed keywords

ALANINE AMINOTRANSFERASE; BEVACIZUMAB; PANOBINOSTAT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; ADVERSE DRUG REACTION; AGED; ANAPLASTIC GLIOMA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOPHOSPHATEMIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; WEIGHT REDUCTION; BRAIN NEOPLASMS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943196028     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov201     Document Type: Erratum

References (27)

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16:Suppl 4:iv1-63.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med. 2005;352(10):987-996.
3. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874-5880.
4. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
6. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
7. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
8. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14(21):7068-7073.
9. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152-1160.
10. Anne M, Sammartino D, Barginear MF, et al. Profile of panobinostat and its potential for treatment in solid tumors: an update. Onco Targets Ther. 2013;6:1613-1624.
11. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21(3):427-436.
12. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12(2):634-642.
13. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.Cancer Res. 2004;64(18):6626-6634.
14. Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 2002;19(2):77-81.
15. Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694-705.
16. Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA. 2003;100(23):13513-13518.
17. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007;11(1):83-95.
18. Mandawat A, Fiskus W, Buckley KM, et al. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Blood. 2010;116(24):5306-5315.
19. Drappatz J, Lee EQ, Hammond S, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012;107(1):133-138.
20. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
21. Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.Acta Neuropathol. 2011;121(2):241-252.
22. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code?. Mol Oncol. 2012;6(6):637-656.
23. Asklund T, Kvarnbrink S, Holmlund C, et al. Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.Anticancer Res. 2012;32(7):2407-2413.
24. Eyupoglu IY, Hahnen E, Buslei R, et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem. 2005;93(4):992-999.
25. Ugur HC, Ramakrishna N, Bello L, et al. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol. 2007;83(3):267-275.
26. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 2007;13(3):1045-1052.
27. Taal W, Oosterkamp HM, Walenkamp AME, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953.